STOCKHOLM, April 29, 2024 /PRNewswire/ -- Medivir AB(NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in hepatocellular carcinoma (HCC) has been accepted for presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress in June 26-29, 2024 in Munich..

斯德哥尔摩，2024年4月29日/PRNewswire/--Medivir AB（NASDAQ:MVIR）（STO:MVIR），一家专注于在高度未满足医疗需求的领域开发癌症创新治疗的制药公司，今天宣布，一份关于福斯特罗西他滨bralpamide（fostrox）+Lenvima®联合治疗肝细胞癌（HCC）的摘要已被接受于2024年6月26日至29日在慕尼黑举行的欧洲医学肿瘤学会（ESMO）胃肠道（GI）癌症大会上发表。。

The abstract, titled 'Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma' will be presented at the conference by Dr Hong Jae Chon, CHA Bundang Medical Center in Korea. Dr Chon is one of the investigators in the ongoing phase Ib/IIa study..

这篇题为“fostroxacitabine bralpamide（fostrox，MIV-818）联合lenvatinib治疗2L/3L肝细胞癌的开放标签Ib/IIa期研究中的肝脏药效学”的摘要将由韩国CHA Bundang医学中心的Hong Jae Chon博士在会议上介绍。Chon博士是正在进行的Ib/IIa期研究的研究人员之一。。

The presentation will include pharmacodynamic data from patients in the ongoing phase Ib/IIa clinical study with fostrox + Lenvima combination, evaluating the impact on normal liver function and DNA damage in tumor cells vs healthy cells. The presentation will also include an update on efficacy endpoints as the study has continued to mature and patients have been able to stay on treatment..

该演讲将包括正在进行的fostrox+Lenvima组合的Ib/IIa期临床研究中患者的药效学数据，评估肿瘤细胞与健康细胞对正常肝功能和DNA损伤的影响。随着研究的不断成熟，患者能够继续接受治疗，本报告还将包括疗效终点的最新信息。。

The poster will be available on Medivir's website after the presentation.

演示后，海报将在Medivir的网站上发布。

For additional information, please contact;

有关更多信息，请联系；

Magnus Christensen, CFO, Medivir AB

Magnus Christensen，Medivir AB首席财务官

Telephone: +46 8 5468 3100

电话：+46 8 5468 3100

E-mail: magnus.christensen@medivir.com

电子邮件：magnus.christensen@medivir.com

About fostrox

关于fostrox

Fostrox is a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. This is achieved by coupling an active chemotherapy (troxacitabine) with a prodrug tail. The prodrug design enables fostrox to be administered orally and travel directly to the liver where the active substance is released locally in the liver.

Fostrox是一种智能化学疗法，可选择性地将细胞杀伤化合物递送至肿瘤，同时最大程度地减少对正常细胞的有害影响。这是通过将活性化疗（曲西他滨）与前药尾部偶联来实现的。前药设计使fostrox能够口服给药，并直接进入肝脏，活性物质在肝脏局部释放。

With this unique mechanism, fostrox has the potential to become the first liver-targeted, orally administered drug that can help patients with various types of liver cancer. A phase 1b monotherapy study with fostrox has been completed and a phase 1b/2a combination study in HCC is ongoing..

凭借这种独特的机制，fostrox有可能成为第一种针对肝脏的口服药物，可以帮助各种类型的肝癌患者。fostrox的1b期单药治疗研究已经完成，HCC的1b/2a期联合研究正在进行中。。

About primary liver cancer

关于原发性肝癌

Primary liver cancer is the third leading cause of cancer-related deaths worldwide and hepatocellular carcinoma (HCC) is the most common cancer that arises in the liver. Although existing therapies for advanced HCC can extend the lives of patients, treatment benefits are insufficient and death rates remain high.

原发性肝癌是全球癌症相关死亡的第三大原因，肝细胞癌（HCC）是肝脏中最常见的癌症。虽然现有的晚期肝癌治疗方法可以延长患者的寿命，但治疗效果不足，死亡率仍然很高。

There are approximately 660,000 patients diagnosed with primary liver cancer per year globally and current five-year survival is less than 20 percent1). HCC is a heterogeneous disease with diverse etiologies, and lacks defining mutations observed in many other cancers. This has contributed to the lack of success of molecularly targeted agents in HCC.

全球每年约有66万名患者被诊断患有原发性肝癌，目前的五年生存率不到20%1）。HCC是一种病因多样的异质性疾病，缺乏在许多其他癌症中观察到的明确突变。这导致分子靶向药物在HCC中缺乏成功。

The limited overall benefit, taken together with the poor overall prognosis for patients with intermediate and advanced HCC, results in a large unmet medical need..

总体效益有限，加上中晚期HCC患者总体预后不佳，导致医疗需求大量未得到满足。。

About Medivir

关于Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects.

Medivir开发创新药物，重点关注未满足医疗需求的癌症。候选药物针对可用疗法有限或缺失的适应症领域，并且有很大的机会为患者提供显着改善。Medivir专注于开发fostroxacitabine bralpamide（fostrox），这是一种智能的靶向化疗，旨在选择性治疗肝癌细胞并尽量减少副作用。

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com..

合作和伙伴关系是Medivir商业模式的重要组成部分，药物开发由Medivir或合伙进行。Medivir的股票（股票代码：MVIR）在纳斯达克斯德哥尔摩的小盘股名单上上市。www.medivir.com。。

1) Rumgay et al.,European Journal of Cancer 2022 vol.161, 108-118.

Rumgay等人，《欧洲癌症杂志2022》，第161卷，108-118页。

This information was brought to you by Cision http://news.cision.com

此信息由Cision提供给您http://news.cision.com

https://news.cision.com/medivir/r/medivir-to-present-data-for-the-combination-of-fostrox---lenvima-in-hcc-at-esmo-gi,c3969603

https://news.cision.com/medivir/r/medivir-to-present-data-for-the-combination-of-fostrox---lenvima-in-hcc-at-esmo-gi，c3969603

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/652/3969603/2766828.pdf

https://mb.cision.com/Main/652/3969603/2766828.pdf

Press release (PDF)

新闻稿（PDF）

View original content:https://www.prnewswire.com/news-releases/medivir-to-present-data-for-the-combination-of-fostrox--lenvima-in-hcc-at-esmo-gi-302129837.html

查看原始内容：https://www.prnewswire.com/news-releases/medivir-to-present-data-for-the-combination-of-fostrox--lenvima-in-hcc-at-esmo-gi-302129837.html

SOURCE Medivir

来源Medivir

Company Codes: Bloomberg:MVIR@SS, ISIN:SE0020181014, RICS:MVIR.ST

公司代码：彭博社：MVIR@SS，ISIN:SE0020181014，RICS:MVIR。装货单